Cart
sales@molnova.com
Ro 09-0680
CAS No. 87112-49-0
Ro 09-0680( —— )
Catalog No. M34400 CAS No. 87112-49-0
Ro 09-0680, a compound derived from Salvia miltiorrhiza, is a potent inhibitor of collagen-induced platelet aggregation in rabbits with potential anti-inflammatory activity for the study of cardiovascular disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRo 09-0680
-
NoteResearch use only, not for human use.
-
Brief DescriptionRo 09-0680, a compound derived from Salvia miltiorrhiza, is a potent inhibitor of collagen-induced platelet aggregation in rabbits with potential anti-inflammatory activity for the study of cardiovascular disease.
-
DescriptionRo 09-0680, a compound derived from Salvia miltiorrhiza, is a potent inhibitor of collagen-induced platelet aggregation in rabbits with potential anti-inflammatory activity for the study of cardiovascular disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number87112-49-0
-
Formula Weight264.32
-
Molecular FormulaC18H16O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C(=O)C2=C(C=CC3=C2C=CC=C3C)C=C1C(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Isethionic acid sodi...
2-Hydroxyethanesulfonate (2-Hydroxyethanesulfonic acid or isethionic acid) is an organosulfur compound containing a short chain alkane sulfonate linked to a hydroxyl group. Mammals are able to endogenously synthesize 2-hydroxyethanesulfonate via taurine through a possible enzymatic deamination process.
-
TGFβ1-IN-3
TGFβ1-IN-3, a diarylhydrazone derivative, inhibits fibroblast activation and proliferation, positioning it as a candidate compound for the treatment of idiopathic pulmonary fibrosis (IPF).
-
Tremelimumab
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
